Next-Generation Regimens for Hepatitis C Virus Infection and Their Role in the Clinic
Thursday, June 29, 2017
1:00 PM (ET), 12:00 PM (CT), 11:00 AM (MT), 10:00 AM (PT)
Assessment of Needs
The IAS–USA offers this state-of-the-art activity on the evolving challenges of managing HCV disease as part of a nationwide continuing medical education (CME) effort for physicians. The current armamentarium of direct-acting antiviral (DAA) treatments for hepatitis C virus (HCV) infection is vast. Among currently available treatments are 1-pill coformulations; US Food and Drug Administration (FDA)–approved pangenotypic regimens; and regimens to treat HCV infection in persons with severe comorbidities such as chronic kidney disease, end-stage renal disease, and decompensated cirrhosis. In light of the possible availability of 2 new coformulations, including the first triple drug regimen for HCV-infected treatment-experienced persons, this webinar will review available data for these currently investigational regimens.
At the conclusion of this webinar, participants will be able to:
- Name 2 investigational HCV regimens pending approval by the FDA
- Describe the safety and efficacy of these investigational DAA regimens
- Describe which HCV-infected individuals might benefit from these regimens, if available
Who Should Attend
This webinar is designed for physicians who have a good understanding of the basics of HCV transmission, testing, and management, and have managed HCV infection in at least 5 patients.
This activity is also relevant to nurse practitioners, registered nurses, physician assistants, registered pharmacists, and other health professionals.
Individual registration is required, even if you are viewing as a group, in order to receive CME credit or a certificate of participation.
Registration closes on Wednesday, June 28, 2017, 4:00 PM (PT).
Certificates will be available after the completion of the evaluation and claim form.
For more information or questions, please contact the registration department at registration“at”iasusa.org or 415-544-9400.
Conflicts of Interest
In the interest of maintaining the independence of its CME activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (eg, faculty, IAS–USA Board members, and program staff) to disclose any financial relationships that they or their spouses or partners have had with commercial companies within the past 12 months. Any real or apparent conflicts of interest of those parties are resolved prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in an IAS–USA CME activity.
Continuing Education Credits
The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The IAS–USA designates this live activity for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is eligible for ANCC credit, see final CNE activity announcement for specific details.
This activity is eligible for ACPE credit, see final CPE activity announcement for specific details.
This activity is part of the IAS–USA national educational effort that is funded, in part, by charitable contributions from commercial companies. Per IAS–USA policy, any effort that uses commercial grants must receive grants from several companies with competing products. Funds are pooled and distributed to activities at the sole discretion of the IAS–USA. Grantors have no input into any activity, including its content, development, or selection of topics or speakers. Generous support for this activity has been received from the following contributors.
Gilead Sciences, Inc
Frequently Asked Questions
View our list of FAQs about attending a webinar.
Please contact the registration department at registration“at”iasusa.org or 415-544-9400.